BIOS 3. Healthcare Delivery Innovation: Robert Pearl - Former CEO @ Kaiser Permanente
Robert Pearl is the former CEO @ The Permanente Medical Group (1999-2017), the nation’s largest medical group, and former president of The Mid-Atlantic Permanente Medical Group (2009-2017). In these roles he led 10,000 physicians, 38,000 staff and was responsible for the nationally recognized medical care of 5 million Kaiser Permanente members on the west and east coasts. Dr. Pearl is nationally recognized as a physician leader on healthcare delivery. He hosts a popular podcast called Fixing Healthcare and is author of a Washington Post Bestseller: “Mistreated: why we think we’re getting good healthcare -- and why we’re usually wrong” (he has generously donated all the proceeds from his book to Doctors Without Borders). More recently, he has started a new weekly podcast - “Coronavirus: The Truth.” He writes regularly on Forbes and teaches at both the Stanford School of Medicine and Stanford Graduate School of Business. Dr. Pearl received his medical degree at Yale and completed a plastic surgery residency at Stanford. Visit his website to learn more.
Technology companies have increasingly focused on the healthcare system, and many are excited by their potential to drive change, decrease costs, and improve outcomes. Dr. Robert Pearl discusses hype versus reality in healthcare delivery innovation and how tech can help - but also hurt.
Topics:
How Kaiser Permanente has become a leader in quality, access, and price
The role of tech in the fee-for-service versus capitation debate
Disruption of the fee-for-service system coming from HAVEN, self-insured employers, and off-shore care partnerships
Hype versus reality in tech: how tech often approaches healthcare innovation wrong
The problem with wearables
Misaligned incentives within healthcare and tech
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.